|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang S, Wang X, Zhou Q, Xu Y, Xia W, Xu W,
Ma Z, Qiu M, You R, Xu L and Yin R: Stereotactic ablative
radiotherapy versus lobectomy for stage I non-small cell lung
cancer: A systematic review. Thorac Cancer. 9:337–347. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hassan O, Ahmad A, Sethi S and Sarkar FH:
Recent updates on the role of microRNAs in prostate cancer. J
Hematol Oncol. 5:92012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Du L and Pertsemlidis A: microRNA
regulation of cell viability and drug sensitivity in lung cancer.
Expert Opin Biol Ther. 12:1221–1239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Acunzo M, Visone R, Romano G, Veronese A,
Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli
G, et al: miR-130a targets MET and induces TRAIL-sensitivity in
NSCLC by downregulating miR-221 and 222. Oncogene. 31:634–642.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ,
Choi E, Na MJ, Park JY, Kang J and Son JW: Combining
microRNA-449a/b with a HDAC inhibitor has a synergistic effect on
growth arrest in lung cancer. Lung Cancer. 76:171–176. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Sempere LF, Guo Y, Korc M,
Kauppinen S, Freemantle SJ and Dmitrovsky E: Involvement of
microRNAs in lung cancer biology and therapy. Transl Res.
157:200–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M
and Enokida H: The microRNA expression signature of bladder cancer
by deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li W, Jin X, Deng X, Zhang G, Zhang B and
Ma L: The putative tumor suppressor microRNA-497 modulates gastric
cancer cell proliferation and invasion by repressing eIF4E. Biochem
Biophys Res Commun. 449:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepatocellular carcinoma. Med Oncol. 31:8442014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L, Zheng W, Song Y, Du X, Tang Y, Nie
J and Han W: miRNA-497 enhances the sensitivity of colorectal
cancer cells to neoadjuvant chemotherapeutic drug. Curr Protein
Pept Sci. 16:310–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shibuya M: Vascular endothelial growth
factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A
crucial target for anti- and pro-angiogenic therapies. Genes
Cancer. 2:1097–1105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Chen J, Guo Y, Wang B and Chu H:
Strategies targeting angiogenesis in advanced non-small cell lung
cancer. Oncotarget. 8:53854–53872. 2017.PubMed/NCBI
|
|
17
|
Guo L, Zhang F, Cai Y and Liu T:
Expression profiling of integrins in lung cancer cells. Pathol Res
Pract. 205:847–853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brower M, Carney DN, Oie HK, Gazdar AF and
Minna JD: Growth of cell lines and clinical specimens of human
non-small cell lung cancer in a serum-free defined medium. Cancer
Res. 46:798–806. 1986.PubMed/NCBI
|
|
19
|
Suzuki S, Takahashi T, Nakamura S, Koike
K, Ariyoshi Y, Takahashi T and Ueda R: Alterations of integrin
expression in human lung cancer. Jpn J Cancer Res. 84:168–174.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Banks-Schlegel SP, Gazdar AF and Harris
CC: Intermediate filament and cross-linked envelope expression in
human lung tumor cell lines. Cancer Res. 45:1187–1197.
1985.PubMed/NCBI
|
|
21
|
Hu X, Shi S, Wang H, Yu X, Wang Q, Jiang
S, Ju D, Ye L and Feng M: Blocking autophagy improves the
anti-tumor activity of afatinib in lung adenocarcinoma with
activating EGFR mutations in vitro and in vivo. Sci Rep.
7:45592017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen QY, Wu LJ, Wu YQ, Lu GH, Jiang ZY,
Zhan JW, Jie Y and Zhou JY: Molecular mechanism of trifluoperazine
induces apoptosis in human A549 lung adenocarcinoma cell lines. Mol
Med Rep. 2:811–817. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giaccone G, Battey J, Gazdar AF, Oie H,
Draoui M and Moody TW: Neuromedin B is present in lung cancer cell
lines. Cancer Res. 52 (Suppl 9):S2732–S2736. 1992.
|
|
24
|
Liu Y, Qiao Y, Hu C, Liu L, Zhou L, Liu B,
Chen H and Jiang X: VEGFR2 inhibition by RNA interference affects
cell proliferation, migration, invasion, and response to radiation
in Calu-1 cells. Clin Transl Oncol. 18:212–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji Y, Strawn TL, Grunz EA, Stevenson MJ,
Lohman AW, Lawrence DA and Fay WP: Multifaceted role of plasminogen
activator inhibitor-1 in regulating early remodeling of vein bypass
grafts. Arterioscler Thromb Vasc Biol. 31:1781–1787. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ferdowsian HR and Beck N: Ethical and
scientific considerations regarding animal testing and research.
PLoS One. 6:e240592011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu L, Qiao Y, Hu C, Liu Y, Xia Y, Wang L,
Liu B, Chen H and Jiang X: Endostatin exerts radiosensitizing
effect in non-small cell lung cancer cells by inhibiting VEGFR2
expression. Clin Transl Oncol. 18:18–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ruan K, Fang X and Ouyang G: MicroRNAs:
Novel regulators in the hallmarks of human cancer. Cancer Lett.
285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rapa I, Votta A, Felice B, Righi L,
Giorcelli J, Scarpa A, Speel EJ, Scagliotti GV, Papotti M and
Volante M: Identification of MicroRNAs differentially expressed in
lung carcinoid subtypes and progression. Neuroendocrinology.
101:246–255. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu A, Lu J, Wang W, Shi C, Han B and Yao
M: Role of miR-497 in VEGF-A-mediated cancer cell growth and
invasion in non-small cell lung cancer. Int J Biochem Cell Biol.
70:118–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S, Mo Y, Midorikawa K, Zhang Z, Huang
G, Ma N, Zhao W, Hiraku Y, Oikawa S and Murata M: The potent tumor
suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal
carcinoma by targeting ANLN and HSPA4L. Oncotarget. 6:35893–35907.
2015.PubMed/NCBI
|
|
33
|
Liu A, Huang C, Cai X, Xu J and Yang D:
Twist promotes angiogenesis in pancreatic cancer by targeting
miR-497/VEGFA axis. Oncotarget. 7:25801–25814. 2016.PubMed/NCBI
|
|
34
|
Yang G, Xiong G, Cao Z, Zheng S, You L,
Zhang T and Zhao Y: miR-497 expression, function and clinical
application in cancer. Oncotarget. 7:55900–55911. 2016.PubMed/NCBI
|
|
35
|
Zhao X, Zhao Z, Xu W, Hou J and Du X:
Down-regulation of miR-497 is associated with poor prognosis in
renal cancer. Int J Clin Exp Pathol. 8:758–764. 2015.PubMed/NCBI
|
|
36
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of miR-195 and
miR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y,
Li PY, Wang M, Lin JS and He XX: miR-497 suppresses angiogenesis
and metastasis of hepatocellular carcinoma by inhibiting VEGFA and
AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wei C, Luo Q, Sun X, Li D, Song H, Li X,
Song J, Hua K and Fang L: MicroRNA-497 induces cell apoptosis by
negatively regulating Bcl-2 protein expression at the
posttranscriptional level in human breast cancer. Int J Clin Exp
Pathol. 8:7729–7739. 2015.PubMed/NCBI
|
|
39
|
Xu S, Fu GB, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: miR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lan J, Xue Y, Chen H, Zhao S, Wu Z, Fang
J, Han C and Lou M: Hypoxia-induced miR-497 decreases glioma cell
sensitivity to TMZ by inhibiting apoptosis. FEBS Lett.
588:3333–3339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han Z, Zhang Y, Yang Q, Liu B, Wu J, Zhang
Y, Yang C and Jiang Y: miR-497 and miR-34a retard lung cancer
growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget.
6:13149–13163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu JW, Wang TX, You L, Zheng LF, Shu H,
Zhang TP and Zhao YP: Insulin-like growth factor 1 receptor
(IGF-1R) as a target of miR-497 and plasma IGF-1R levels associated
with TNM stage of pancreatic cancer. PLoS One. 9:e928472014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pengcheng S, Ziqi W, Luyao Y, Xiangwei Z,
Liang L, Yuwei L, Lechen L and Wanhai X: MicroRNA-497 suppresses
renal cell carcinoma by targeting VEGFR-2 in ACHN cells. Biosci
Rep. 37:BSR201702702017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shi L, Zhang S, Wu H, Zhang L, Dai X, Hu
J, Xue J, Liu T, Liang Y and Wu G: miR-200c increases the
radiosensitivity of non-small-cell lung cancer cell line A549 by
targeting VEGF-VEGFR2 pathway. PLoS One. 8:e783442013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hosomi Y, Yoh K, Kasahara K, Yamada K,
Takahashi T, Hida TTK, Yoshioka H, Kato T, Takeda K, Nishio M, et
al: Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as
second-line treatment for advanced non-small cell lung cancer
(NSCLC): A randomized, phase II, double-blind, multicenter trial in
Japan. J Clin Oncol. 33:8054. 2015. View Article : Google Scholar
|
|
48
|
Ding M, Liu L, Hu C, Liu Y, Qiao Y and
Jiang X: Expression of VEGFR2 and NRP-1 in non-small cell lung
cancer and their clinical significance. Chin J Cancer Res.
26:669–677. 2014.PubMed/NCBI
|
|
49
|
Devery AM, Wadekar R, Bokobza SM, Weber
AM, Jiang Y and Ryan AJ: Vascular endothelial growth factor
directly stimulates tumour cell proliferation in non-small cell
lung cancer. Int J Oncol. 47:849–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhu J, Zeng Y, Li W, Qin H, Lei Z, Shen D,
Gu D, Huang JA and Liu Z: CD73/NT5E is a target of miR-30a-5p and
plays an important role in the pathogenesis of non-small cell lung
cancer. Mol Cancer. 16:342017. View Article : Google Scholar : PubMed/NCBI
|
